Genetic manipulation and genetic variation of the kallikrein-kinin system: Impact on cardiovascular and renal diseases

Progress in Drug Research

Volumn 69, Issue , 2014, Pages 145-196

  Girolami, Jean Pierre ^a   Blaes, Nelly ^a   Bouby, Nadine ^a   Alhenc Gelas, François ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; ELECTROLYTE; KININ; KININOGEN; PLASMA KALLIKREIN; PLASMA PREKALLIKREIN; PREKALLIKREIN; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ACE GENE; ANTIANGIOGENIC ACTIVITY; ARTICLE; B1R GENE; B2R GENE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DNA MODIFICATION; ELECTROLYTE EXCRETION; FLUID BALANCE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENE THERAPY; GENETIC MANIPULATION; GENETIC MODEL; GENETIC VARIABILITY; GLUCOSE METABOLISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; KIDNEY DISEASE; LOSS OF FUNCTION MUTATION; MOUSE MODEL; NONHUMAN; PERIPHERAL ISCHEMIA; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RENAL PROTECTION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE KALLIKREIN GENE;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; KALLIKREINS; KIDNEY DISEASES; KININS; PHENOTYPE; RENAL AGENTS; SIGNAL TRANSDUCTION;

EID: 84904384653     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-319-06683-7_6     Document Type: Article

References (334)

1. Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr (2005) Angiotensin- converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46:821-826
2. Adam A, Leclair P, Montpas N et al (2010) Altered cardiac bradykinin metabolism in experimental diabetes caused by the variations of angiotensin-converting enzyme and other peptidases. Neuropeptides 44:69-75
3. Agata J, Chao L, Chao J (2002) Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 40:653-659
4. Ahmad M, Zeitlin IJ, Parratt JR, Kolar F (1996) Kinin release from normally perfused and ischaemic isolated rat hearts: effect of strain. Immunopharmacology 33:297-298
5. Alfie ME, Yang XP, Hess F, Carretero OA (1996) Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224:625-630
6. Alhenc-Gelas F, Tsai SJ, Callahan K et al (1982) Stimulation of prostaglandin formation by vasoactive mediators in cultured human endothelial cells. Prostaglandins 24(5):723-42
7. Alhenc-Gelas F, Baussant T, Hubert C et al (1989) The angiotensin converting enzyme in the kidney. J Hypertens Suppl 7:S9-S13
8. Alhenc-Gelas F, Richard J, Courbon D et al (1991) Distribution of plasma aniotensin I-converting enzyme levels in healthy men: relationship to environmental and hormonal parameters. J Lab Clin Med 117(1):33-9
9. Alhenc-Gelas F, Corvol P (2000) Molecular and physiological aspect of angiotensin I-converting enzyme. In: Fray JS, Goodman HS (eds) "Handbook of Physiology", section 7, vol III, American physiological society and Oxford university Press publishers, New-York, USA
10. Alhenc-Gelas F, Bouby N, Richer C et al (2011) Kinins as therapeutic agents in cardiovascular and renal diseases. Curr Pharm Des 17:2654-2662
11. Alhenc-Gelas F, Girolami JP (2011) Molecular and genetic aspects of the Kallikrein-kinin system. In: Bader M (ed) "Kinins", De Gruyter, Berlin, Germany, pp 7-32
12. Allard J, Buléon M, Cellier E et al (2007) ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 293:F1083-F1092
13. Alves CR, Alves GB, Pereira AC et al (2013) Vascular reactivity and ACE activity response to exercise training are modulated by the +9/-9 bradykinin B2 receptor gene functional polymorphism. Physiol Genomics 45:487-492
14. Amorim CE, Nogueira E, Almeida SS et al (2013) Clinical impact of an ace insertion/deletion and kinin B2 receptor +9/-9 polymorphisms in the prognosis of renal transplantation. Biol Chem 394:369-377
15. Aoki S, Mukae S, Itoh S et al (2001) The genetic factor in acute myocardial infarction with hyprertension. Jpn Circ J 65:621-626
16. Araújo RC, Mori MA, Merino VF et al (2006) Role of the kinin B1 receptor in insulin homeostasis and pancreatic islet function. Biol Chem 387:431-436
17. Asselbergs FW, Williams SM, Hebert Coffey CS et al (2006) The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 96:471-477
18. Asselbergs FW, Williams SM, Hebert PR et al (2007a) The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context. Hum Genet 122:275-281
19. Asselbergs FW, Williams SM, Hebert Coffey CS et al (2007b) Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. Genomics 89:362-369
20. Azizi M, Boutouyrie P, Bissery A et al (2005) Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 115:780-787
21. Azizi M, Emanueli C, Peyrard S et al (2008) Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins excretion in man. J Hypertens 26:714-720
22. Bachvarov DR, Landry M, Houle S et al (1998a) Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. Gastroenterology 115:1045-1048
23. Bachvarov DR, Landry M, Pelletier I et al (1998b) Characterization of two polymorphic sites in the human kinin B1 receptor gene: altered frequency of an allele in patients with a history of end-stage renal failure. J Am Soc Nephrol 9:598-604
24. Bao G, Gohlke P, Qadri F, Unger T (1992) Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 20:74-79
25. Barros CC, Haro A, Russo FJ et al (2012a) Altered glucose homeostasis and hepatic function in obese mice deficient for both kinin receptor genes. PLoS ONE 7:e40573
26. Barros CC, Haro A, Russo FJ et al (2012b) Bradykinin inhibits hepatic gluconeogenesis in obese mice. Lab Invest 92:1419-1427
27. Bas M, Hoffmann TK, Tiemann B et al (2010) Potential genetic risk factors in angiotensinconverting enzyme-inhibitor-induced angio-oedema. Br J Clin Pharmacol 69:179-186
28. Baumgarten CR, Linz W, Kunkel G et al (1993) Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 108:293-295
29. Baydoun AR, Woodward B (1991) Effects of bradykinin in the rat isolated perfused heart: role of kinin receptors and endothelium-derived relaxing factor. Br J Pharmacol 103:1829-1833
30. Beard KM, Lu H, Ho K, Fantus IG (2006) Bradykinin augments insulin-stimulated glucose transport in rat adipocytes via endothelial nitric oxide synthase-mediated inhibition of Jun NH2-terminal kinase. Diabetes 55:2678-2687
31. Belanger S, Bovenzi V, Côté J et al (2009) Structure-activity relationships of novel peptide agonists of the human bradykinin B2 receptor. Peptides 30:777-787
32. Bentley JP, Asselbergs FW, Coffey CS et al (2010) Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems. PLoS ONE 2010(5):e12757. doi:10.1371/journal.pone.0012757
33. Bergaya S, Meneton P, Bloch-Faure M et al (2001) Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88:593-599
34. Bergaya S, Hilgers RH, Meneton P et al (2004) Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res 94:1623-1629
35. Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14:39-47
36. Bernstein KE, Giani JF, Shen XZ, Gonzalez-Villalobos RA (2014) Renal angiotensin-converting enzyme and blood pressure control. Curr Opin Nephrol Hypertens 23:106-112
37. Berry TD, Hasstedt SJ, Hunt SC et al (1989) A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 13:3-8
38. Bhupatiraju C, Patkar S, Pandharpurkar D et al (2012) Association and interaction of -58CT and ±9 bp polymorphisms of BDKRB2 gene causing susceptibility to essential hypertension. Clin Exp Hypertens 34:230-235
39. Björkqvist J, Sala-Cunill A, Renné T (2013) Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 109:368-374
40. Blaes N, Pécher C, Mehrenberger M et al (2012) Bradykinin inhibits high glucose-and growth factor-induced collagen synthesis in mesangial cells through the B2-kinin receptor. Am J Physiol Renal Physiol 303:F293-F303
41. Blaes N, Girolami JP (2013) Targetting the janus face if the B2-bradykinin receptor. Expert Opin Ther Target 17:1145-1166
42. Blanchard A, Azizi M, Peyrard S et al (2007) Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling. Clin J Am Soc Nephrol 2:320-325
43. Bodin S, Chollet C, Goncalves-Mendes N et al (2009) Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 76:395-403
44. Borkowski JA, Ransom RW, Seabrook GR et al (1995) Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270:13706-13710
45. Bosch J, Yusuf S, Gerstein HC et al (2006) Effect of ramipril on the incidence of diabetes. DREAM trial investigators. N Engl J Med 355:1551-1562
46. Braun A, Kammerer S, Bohme E et al (1995) Identification of polymorphic sites of the human bradykinin B2 receptor gene. Biochem Biophys Res Commun 211:234-240
47. Braun A, Kammerer S, Maier E et al (1996a) Polymorphisms in the gene for the human B2- bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology 33:32-35
48. Braun A, Maier E, Kammerer S et al (1996b) A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene. Hum Genet 97:688-689
49. Brochu I, Houde M, Desbiens L et al (2013) High salt-induced hypertension in B2 knockout mice is corrected by the ETA antagonist, A127722. Br J Pharmacol 170:266-277
50. Brugts JJ, Isaacs A, Boersma E et al (2010) Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. Eur Heart J 31:1854-1864
51. Brugts JJ, Isaacs A, de Maat MP et al (2011) A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens 29:509-519
52. Brugts JJ, de Maat MP, Danser AH et al (2012) Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Neth Heart J 20:24-32
53. Brull D, Dhamrait S, Myerson S et al (2001) Bradykinin B2BKR receptor polymorphism and leftventricular growth response. Lancet 358:1155-1156
54. Buléon M, Allard J, Jaafar A et al (2008) Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model. Am J Physiol Renal Physiol 294:F1249-F1256
55. Cambien F, Alhenc-Gelas F, Herbeth B et al (1988) Familial resemblance of plasma angiotensinconverting enzyme level: the nancy study. Am J Hum Genet 43:774-780
56. Cambien F, Poirier O, Lecerf L et al (1992) Deletion polymorphism in the gene for angiotensinconverting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644
57. Cambien F, Costerousse O, Tiret L et al (1994) Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 90:669-976
58. Campbell DJ, Alexiou T, Xiao HD et al (2004) Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension 43:854-859
59. Campbell DJ, Kladis A, Zhang Y et al (2010) Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 53:779-785
60. Campbell WB, Gebremedhin D, Pratt PF, Harder DR (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78(3):415-23
61. Cardoso CC, Garrett T, Cayla C et al (2004) Structure and expression of two kininogen genes in mice. Biol Chem 385:295-301
62. Carvalho CR, Thirone AC, Gontijo JA et al (1997) Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46:1950-1957
63. Catanzaro OL, Dziubecki D, Obregon P et al ((2010) Antidiabetic efficacy of bradykinin antagonist R-954 on glucose tolerance test in diabetic type 1 mice. Neuropeptides 44:187-189
64. Cayla C, Todiras M, Iliescu R et al (2007) Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 21:1689-1698
65. Cervenka L, Maly J, Karasová L et al (2001) Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension 37:967-973
66. Chahine R, Adam A, Yamaguchi N et al (1993) Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. Br J Pharmacol 108:318-322
67. Chambrey R, Picard N (2011) Role of tissue kallikrein in regulation of tubule function. Curr Opin Nephrol Hypertens 20:523-528
68. Chao J, Zhang JJ, Lin KF, Chao L (1998) Human kallikrein gene delivery attenuates hypertension, cardiac hypertrophy, and renal injury in Dahl salt-sensitive rats. Hum Gene Ther 9:21-31
69. Chao J, Yin H, Gao L et al (2008) Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kininformation. Hypertension 52:715-720
70. Chen S, Zhou Y, Li J et al (2012) The effect of bradykinin B2 receptor polymorphisms on the susceptibility and severity of osteoarthritis in a Chinese cohort. J Biomed Biotechnol 2012(2012):597637
71. Cicardi M, Banerji A, Bracho F et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532-541
72. Clermont A, Chilcote TJ, Kita T et al (2011) Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes 60:1590-1598
73. Côte J, Savard M, Bovenzi V et al (2009) Novel kinin B1 receptor agonists with improved pharmacological profiles. Peptides 30:788-795
74. Côte J, Savard M, Bovenzi V et al (2010) Selective tumor blood-brain barrier opening with the kinin B2 receptor agonist [Phe(8)psi(CH(2)NH)Arg(9)]-BK in a F98 glioma rat model: an MRI study. Neuropeptides 44:177-185
75. Cui J, Melista E, Chazaro I et al (2005) Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J Hypertens 23:55-62
76. Couture R, Girolami JP (2004) Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur J Pharmacol 500:467-485
77. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F (1993) Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 290:33-40
78. Costerousse O, Danilov S, Alhenc-Gelas F (1997) Genetics of angiotensin I-converting enzyme. Clin Exp Hypertens 19:659-669
79. Damas J, Adam A (1980) Congenital deficiency in plasma kallikrein and kininogens in the brown Norway rat. Experientia 36:586-587
80. Danser AH, Schalekamp MA, Bax WA et al (1995) Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92:1387-1388
81. de Oliveira Alvim R, Santos PC, Nascimento RM et al (2012) BDKRB2 +9/-9 polymorphism is associated with higher risk for diabetes Mellitus in the Brazilian general population. Exp Diabetes Res 2012:480251
82. de Picoli Souza K, Batista EC, Silva ED et al (2010) Effect of kinin B2 receptor ablation on skeletal muscle development and myostatin gene expression. Neuropeptides 44:209-214
83. Dhamrait SS, Payne JR, Li P, Jones A et al (2003) Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J 24:1672-1680
84. Dias JP, Talbot S, Sénécal J et al (2010) Kinin B1 receptor enhances the oxidative stress in a rat model of insulin resistance: outcome in hypertension, allodynia and metabolic complications. PLoS ONE 5:e12622
85. Dias JP, Couture R (2012) Blockade of kinin B(1) receptor reverses plasma fatty acids composition changes and body and tissue fat gain in a rat model of insulin resistance. Diabetes Obes Metab 4:244-253
86. Dietze GJ, Wicklmayr M, Rett K et al (1996) Potential role of bradykinin in forearm muscle metabolism in humans. Diabetes 45:S110-S114
87. Doria A, Warram JH, Krolewski AS (1994) Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 43:690-695
88. Duka I, Kintsurashvili E, Gavras I et al (2001) Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res 88:275-281
89. Ehlers MR, Fox EA, Strydom DJ, Riordan JF (1989) Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc Natl Acad Sci USA 86:7741-7745
90. El-Dorry HA, Bull HG, Iwata K et al (1982) Molecular and catalytic properties of rabbit testicular dipeptidyl carboxypeptidase. J Biol Chem 257:14128-14133
91. El Moghrabi S, Houillier P, Picard N et al (2010) Tissue kallikrein permits early renal adaptation to potassium load. Proc Natl Acad Sci USA 107:13526-13531
92. Emanueli C, Fink E, Milia AF et al (1998) Enhanced blood pressure sensitivity to deoxycorticosterone in mice with disruption of bradykinin B2 receptor gene. Hypertension 31:1278-1283
93. Emanueli C, Minasi A, Zacheo A et al (2001a) Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Circulation 103:125-132
94. Emanueli C, Salis MB, Stacca T et al (2001b) Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 38:136-141
95. Emanueli C, Bonaria Salis M et al (2002) Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 105:360-366
96. Emanueli C, Graiani G, Salis MB et al (2004a) Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 53:1096-1103
97. Emanueli C, Salis MB, Van Linthout S et al (2004b) Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110:1638-1644
98. Erdmann J, Hegemann N, Weidemann A, Kallisch H et al (1998) Screening the human bradykinin B2 receptor gene in patients with cardiovascular diseases: identification of a functional mutation in the promoter and a new coding variant (T21 M). Am J Med Genet 80:521-525
99. Erdös EG (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 16:363-370
100. Esther CR Jr, Howard TE, Marino EM et al (1996) Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74:953-965
101. Eynon N, Meckel Y, Alves AJ et al (2011) Is there an interaction between BDKRB2 -9/+9 and GNB3 C825T polymorphisms and elite athletic performance? Scand J Med Sci Sports 21:e242-e246
102. Fallo F, Mulatero P, Vettor R et al (2004) Bradykinin B2 receptor gene C-58T polymorphism and insulin resistance. A study on obese patients. Horm Metab Res 36:243-246
103. Fan H, Stefkova J, El-Dahr SS (2006) Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway. Am J Physiol Renal Physiol 291:F670-F682
104. Feener EP, Zhou Q, Fickweiler W (2013) Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost 110:434-441
105. Fischer M, Lieb W, Marold D et al (2004) Lack of association of a 9 bp insertion/deletion polymorphism within the bradykinin 2 receptor gene with myocardial infarction. Clin Sci (Lond) 107:505-511
106. Fogari R, Zoppi A, Salvadeo SA et al (2011) Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res 34:509-515
107. Freiberger T, Vyskocilová M, Kolárová L et al (2002) Exon 1 polymorphism of the B2BKR gene does not influence the clinical status of patients with hereditary angioedema. Hum Immunol 63:492-494
108. Freitas SR, Pereira AC, Floriano MS et al (2009) Insertion/deletion polymorphism of the bradykinin type 2 receptor gene influence diastolic blood pressure. J Hum Hypertens 23:553-555. doi:10.1038/jhh.2009.23
109. Fu Y, Katsuya T, Matsuo A et al (2004) Relationship of bradykinin B2 receptor gene polymorphism with essential hypertension and left ventricular hypertrophy. Hypertens Res 27:933-938
110. Fujihara Y, Tokuhiro K, Muro Y et al (2013) Expression of TEX101, regulated by ACE, is essential for the production of fertile mouse spermatozoa. Proc Natl Acad Sci USA 110:8111-8116
111. Fujisawa T, Ikegami H, Shen GQ et al (1995) Angiotensin I-converting enzyme gene polymorphism is associated with myocardial infarction, but not with retinopathy or nephropathy, in NIDDM. Diabetes Care 18:983-985
112. Furchgott RF, Vanhoutte PM (1989) Endothelium-derived relaxing and contracting factors. FASEB J 3(9):2007-18
113. Gainer JV, Brown NJ, Bachvarova M et al (2000) Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens 13:1268-1273
114. Gkika D, Topala CN, Chang Q et al (2006) Tissue kallikrein stimulates Ca(2+) reabsorption via PKC-dependent plasma membrane accumulation of TRPV5. EMBO J 25:4707-4716
115. Gao BB, Clermont A, Rook S et al (2007) Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13:181-188
116. Girolami JP, Bascands JL, Pécher C et al (1989a) Renal kallikrein excretion as a distal nephrotoxicity marker during cadmium exposure in rats. Toxicology 55:117-129
117. Girolami JP, Orfila C, Pecher C et al (1989b) Inverse relationship between renal and urinary kallikrein during chromate-induced acute renal failure in rat: urinary kallikrein excretion as a possible recovery index. Biol Chem Hoppe Seyler 370:1305-1313
118. Glotov AS, Ivashchenko TE, Obraztsova GI et al (2007) Renin-angiotensin and kinin-bradykinin genes polymorphism effects on permanent arterial hypertension in children. Mol Biol (Mosk) 41:18-25
119. Göbel K, Pankratz S, Schneider-Hohendorf T et al (2011) Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 36:106-114
120. Gohlke P, Lamberty V, Kuwer I et al (1993) Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate. Hypertension 22:682-687
121. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK et al (2013) The absence of intrarenal ACE protects against hypertension. J Clin Invest 123:2011-2023
122. Gratacòs M, Costas J, de Cid R et al (2009) Psychiatric genetics network group. Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment. Am J Med Genet B Neuropsychiatr Genet 150B:808-816. doi:10.1002/ ajmg.b.30902
123. Grilo A, Sáez-Rosas MP, Santos-Morano J et al (2011) Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genomics 21:10-17
124. Griol-Charhbili V, Messadi-Laribi E, Bascands JL et al (2005) Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 19:1172-1174
125. Griol-Charhbili V, Sabbah L, Colucci J et al (2009) Tissue kallikrein deficiency and renovascular hypertension in the mouse. Am J Physiol Regul Integr Comp Physiol 296:R1385-R1391
126. Groves P, Kurz S, Just H, Drexler H (1995) Role of endogenous bradykinin in human coronary vasomotor control. Circulation 92:3424-3430
127. Gu D, Zhao Q, Kelly TN et al (2012) The role of the kallikrein-kinin system genes in the salt sensitivity of blood pressure: the gensalt study. Am J Epidemiol 176:S72-S80
128. Haberbosch W, Bohle RM, Franke FE et al (1997) The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis 130(1-2):203- 13
129. Hallberg P, Lind L, Michaelsson K et al (2003) B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) trial. J Hypertens 21:621-624
130. Hashimoto K, Hamamoto H, Honda Y et al (1978) Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am Heart J 95:619-626
131. Hebert RL, Regoli D, Xiong H et al (2005) Bradykinin B2 type receptor activation regulates fluid and electrolyte transport in the rabbit kidney. Peptides 26:1308-1316
132. Hecker M, Bara AT, Bauersachs J, Busse R (1994) Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 481(Pt 2):407-14
133. Henriksen EJ, Jacob S, Fogt DL, Dietze GJ et al (1998) Effect of chronic bradykinin administration on insulin action in an animal model of insulin resistance. Am J Physiol 275:R40-R45
134. Hess JF, Borkowski JA, Young GS et al (1992) Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 184(2):60-268
135. Hillmeister P, Gatzke N, Dülsner A et al (2011) Arteriogenesis is modulated by bradykinin receptor signaling. Circ Res 109:524-533
136. Hiyoshi H, Yayama K, Takano M, Okamoto H (2004) Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension 43:1258-1263
137. Holland OB, Chud JM, Braunstein H (1980) Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest 65:347-356
138. Hopkinson NS, Eleftheriou KI, Payne J et al (2006) +9/+9 Homozygosity of the bradykinin receptor gene polymorphism is associated with reduced fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 83:912-917
139. Horwitz D, Margolius HS, Keiser HR (1978) Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab 47:296-299
140. Houle S, Landry M, Audet R et al (2000) Effect of allelic polymorphism of the B(1) and B(2) receptor genes on the contractile responses of the human umbilical vein to kinins. J Pharmacol Exp Ther 294:45-51
141. Huang W, Gallois Y, Bouby N et al (2001) Genetically increased angiotensin I-converting enzyme level and renal complications in diabetic mouse. Proc Natl Acad Sci USA 98:13330-13334
142. Jaffa AA, Rust PF, Mayfield RK (1995) Kinin, a mediator of diabetes-induced glomerular hyperfiltration. Diabetes 44:156-160
143. Jeunemaitre X, Lifton RP, Hunt SC et al (1992) Absence of linkage between the angiotensin converting enzyme locus and human essential hypertension. Nat Genet 1:72-75
144. Jozwiak L, Drop A, Buraczynska K, Ksiazek P, Mierzicki P, Buraczynska M (2004) Association of the human bradykinin B2 receptor gene with chronic renal failure. Mol Diagn 8:157-161
145. Kakoki M, Takahashi N, Jennette JC, Smithies O (2004) Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 101:13302-13305
146. Kakoki M, Kizer CM, Yi X et al (2006) Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest 116:1302-1309
147. Kakoki M, McGarrah RW, Kim HS, Smithies O (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104:7576-7581
148. Kakoki M, Smithies O (2009) The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 75:1019-1030
149. Kakoki M, Sullivan KA, Backus C et al (2010) Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci USA 107:10190-10195
150. Kammerer S, Braun A, Arnold N, Roscher AA (1995) The human bradykinin B2 receptor gene: full length cDNA, genomic organization and identification of the regulatory region. Biochem Biophys Res Commun 211:226-233
151. Katori M, Majima M (2003) The renal kallikrein-kinin system: its role as a safety valve for excess sodium intake, and its attenuation as a possible etiologic factor in salt-sensitive hypertension. Crit Rev Clin Lab Sci 40:43-115
152. Kayashima Y, Smithies O, Kakoki M (2012) The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens 21:92-96
153. Kishi K, Muromoto N, Nakaya Y et al (1998) Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 47:550-558
154. Keavney BD, Dudley CR, Stratton IM et al (1995) UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme insertion/deletion polymorphism with myocardial infarction in NIDDM. Diabetologia 38:948-952
155. Klein J, Gonzalez J, Duchene J et al (2009) Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 23:134-142
156. Knigge H, Bluthner M, Bruntgens A et al (2000) G(-699)/C polymorphism in the bradykinin-1 receptor gene in patients with renal failure. Nephrol Dial Transplant 15:586-588
157. Koch M, Spillmann F, Dendorfer A et al (2006) Cardiac function and remodeling is attenuated in transgenic rats expressing the human kallikrein-1 gene after myocardial infarction. Eur J Pharmacol 550:143-148
158. Kränkel N, Katare RG, Siragusa M et al (2008) Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circ Res 103:1335-1343
159. Krege JH, John SW, Langenbach LL et al (1995) Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375:146-148
160. Krege JH, Kim HS, Moyer JS et al (1997) Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. Hypertension 29:150-157
161. Kusser B, Braun A, Praun M et al (2001) Polymorphisms in the bradykinin B2 receptor gene and childhood asthma. Biol Chem 382:885-889
162. Kwak SJ, Paeng J, Kim do H et al (2011) Local kallikrein-kinin system is involved in podocyte apoptosis under diabetic conditions. Apoptosis 16:478-490
163. Lachurié ML, Azizi M, Guyene TT et al (1995) Angiotensin- converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Circulation 91:2933-2942
164. Lagneux C, Bader M, Pesquero JB et al (2002) Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int Immunopharmacol 2:815-822
165. Lan W, Yang F, Liu L et al (2013) Tissue kallikrein preventing the restenosis after stenting of symptomatic MCA atherosclerotic stenosis (KPRASS). Int J Stroke. (In press)
166. Langhauser F, Göb E, Kraft P et al (2012) Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 120:4082-4092
167. Lattion AL, Baussant T, Alhenc-Gelas F et al (1988) The high-molecular-mass kininogen deficient rat expresses all kininogen mRNA species, but does not export the high-molecularmass kininogen synthesized. FEBS Lett 239:59-64
168. Lattion AL, Soubrier F, Allegrini J et al (1989) The testicular transcript of the angiotensin Iconverting enzyme encodes for the ancestral, non-duplicated form of the enzyme. FEBS Lett 252:99-104
169. Lee YJ, Tsai JC (2001) Angiotensin-converting enzyme gene insertion/deletion, not bradykinin B2 receptor -58T/C gene polymorphism, associated with angiotensin-converting enzyme inhibitor-related cough in Chinese female patients with non-insulin-dependent diabetes mellitus. Metabolism 50(1):346-1350
170. Li YY, Zhang H, Xu J et al (2012) Bradykinin beta2 receptor -58T/C gene polymorphism and essential hypertension: a meta-analysis. PLoS ONE 7:e43068
171. Liesmaa I, Shiota N, Kokkonen JO et al (2012) Bradykinin type-2 receptor expression correlates with age and is subjected to transcriptional regulation. Int J Vasc Med 2012(2012):159646
172. Lindpaintner K, Lee M, Larson MG et al (1996) Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med 334:1023-1028159646
173. Linz W, Wiemer G, Gohlke P et al (1995) Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47:25-49
174. Liu J, Feener EP (2013) Plasma kallikrein-kinin system and diabetic retinopathy. Biol Chem 394:319-328
175. Liu J, Gao BB, Clermont AC et al (2011) Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med 17:206-210
176. Lochner W, Parratt JR (1996) A comparison of the effects of locally and systemically administered kinins on coronary blood flow and myocardial metabolism. Br J Pharmacol Chemother. 26:17-26
177. Lortie M, Regoli D, Rhaleb NE, Plante GE (1992) The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol 262:R72-R76
178. Lu J, Li LM, Zhan SY et al (2003) [Study on candidate genes of benazepril related cough in Chinese hypertensives]. Zhonghua Liu Xing Bing Xue Za Zhi 24:498-502
179. Lung CC, Chan EK, Zuraw BL (1997) Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol 99:134-146
180. Madeddu P, Milia AF, Salis MB et al (1998) Renovascular hypertension in bradykinin B2- receptor knockout mice. Hypertension 32:503-509
181. Madeddu P, Emanueli C, Gaspa L et al (1999) Role of the bradykinin B2 receptor in the maturation of blood pressure phenotype: lesson from transgenic and knockout mice. Immunopharmacology. 44:9-13
182. Madeddu P, Emanueli C, El-Dahr S (2007) Mechanisms of disease: the tissue kallikrein-kinin system in hypertension and vascular remodeling. Nat Clin Pract Nephrol 3:208-221
183. Maestri R, Milia AF, Salis MB et al (2003) Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 41:1151-1155
184. Mage M, Pécher C, Neau E et al (2002) Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol 80:328-333
185. Mahajan H, Richards SM, Rattigan S, Clark MG (2004) Local methacholine but not bradykinin potentiates insulin-mediated glucose uptake in muscle in vivo by augmenting capillary recruitment. Diabetologia 47:2226-2234
186. Maltais I, Bachvarova M, Maheux P et al (2002) Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/creatinine values in diabetic patients. Can J Physiol Pharmacol 80:323-332
187. Marchetti J, Imbert-Teboul M, Alhenc-Gelas F et al (1984) Kallikrein along the rabbit microdissected nephron. A micromethod for its measurement. Pflugers Archiv 401(1):27-33
188. Marcon R, Claudino RF, Dutra RC et al (2013) Exacerbation of DSS-induced colitis in mice lacking kinin B(1) receptors through compensatory up-regulation of kinin B(2) receptors: the role of tight junctions and intestinal homeostasis. Br J Pharmacol 168:389-402
189. Margolius HS, Geller RG, De Jong W et al (1972) Urinary kallikrein excretion in hypertension. Circ Res 31:125-131
190. Margolius HS, Horwitz D, Pisano JJ, Keiser HR (1976) Relationships among urinary kallikrein, mineralocorticoids and human hypertensivedisease. Fed Proc 35:203-206
191. Margolius HS (1989) Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol Toxicol 29:343-364
192. Marin-Castaño ME, Schanstra JP, Neau E et al (2002) Induction of functional bradykinin b(1)- receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation 105:627-632
193. Marketou M, Kintsurashvili E, Papanicolaou KN et al (2010) Cardioprotective effects of a selective B(2) receptor agonist of bradykinin post-acute myocardial infarct. Am J Hypertens 23:562-568
194. Marre M, Bernadet P, Gallois Y et al (1994) Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 43:384-388
195. Marre M, Jeunemaitre X, Gallois Y et al (1997) Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 99:1585-1595
196. Mayfield RK, Margolius HS, Levine JH et al (1984) Urinary kallikrein excretion in insulindependent diabetes mellitus and its relationship to glycemic control. J Clin Endocrinol Metab 59:278-286
197. Mas S, Gassò P, Alvarez S et al (2011) Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet Genomics 21:531-538
198. McEachern AE, Shelton ER, Bhakta S et al (1991) Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 88:7724-7728
199. Menke JG, Borkowski JA, Bierilo KK et al (1994) Expression cloning of a human B1 bradykinin receptor. J Biol Chem 269:21583-21586
200. Merkulov S, Zhang WM, Komar AA et al (2008) Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 111:1274-1281
201. Meneton P, Bloch-Faure M, Hagege AA et al (2001) Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98:2634-2639
202. Merino VF, Todiras M, Campos LA et al (2008) Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. J Mol Med (Berl) 86:791-798
203. Merino VF, Todiras M, Mori MA et al (2009) Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E. J Mol Med (Berl) 87:953-963
204. Messadi-Laribi E, Griol-Charhbili V, Pizard A et al (2007) Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther 323:210-216
205. Messadi E, Vincent MP, Griol-Charhbili V et al (2010) Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia. FASEB J 24:4691-4700
206. Metzger R, Bohle RM, Pauls K et al (1999) Angiotensin-converting enzyme in non-neoplastic kidney diseases. Kidney Int 56:1442-1454
207. Metzger R, Franke FE, Bohle RM et al (2011) Heterogeneous distribution of angiotensin Iconverting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity. Microvasc Res 81:206-215
208. Milan A, Mulatero P, Williams TA et al (2005) Bradykinin B2 receptor gene (-58T/C) polymorphism influences baroreflex sensitivity in never-treated hypertensive patients. J Hypertens 23:63-69
209. Mitas JA, Levy SB, Holle R et al (1978) Urinary kallikrein activity in the hypertension of renal parenchymal disease. N Engl J Med 299:162-165
210. Miura S, Matsuo Y, Saku K (2003) Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 41:1118-2113
211. Moholisa RR, Rayner BR, Patricia Owen E et al (2013) Association of B2 receptor polymorphisms and ACE activity with ACE inhibitor-induced angioedema in black and mixed-race South Africans. J Clin Hypertens 15:413-419
212. Montanari D, Yin H, Dobrzynski E et al (2005) Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. Diabetes 54:1573-1580
213. Montasser ME, Gu D, Chen J et al (2011) Interactions of genetic variants with physical activity are associated with blood pressure in Chinese: the GenSalt study. Am J Hypertens 24:1035-1040
214. Monteiro JS, Blanchard A, Curis E et al (2013) Partial genetic deficiency in tissue kallikrein impairs adaptation to high potassium intake in humans. Kidney Int 84:1271-1277
215. Mori MA, Araújo RC, Reis FC et al (2008) Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes 57:1491-1500
216. Mori MA, Sales VM, Motta FL, et al (2012) Kinin B1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity. PLoS One:e44782
217. Mukae S, Aoki S, Itoh S et al (1999) Promoter polymorphism of the beta2 bradykinin receptor gene is associated with essential hypertension. Jpn Circ J 63:759-762
218. Mukae S, Aoki S, Itoh S et al (2000) Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension 36:127-131
219. Mukae S, Itoh S, Aoki S et al (2002) Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens 16:857-863
220. Mulatero P, Williams TA, Milan A et al (2002) Blood pressure in patients with primary aldosteronism is influenced by bradykinin B(2) receptor and alpha-adducin gene polymorphisms. J Clin Endocrinol Metab 87:3337-3343
221. Munk VC, Sanchez de Miguel L, Petrimpol M, et al (2007) Angiotensin II induces angiogenesis in the hypoxic adult mouse heart in vitro through an AT2-B2 receptor pathway. Hypertension 49:1178-1185
222. Muromoto N, Nakaya Y et al (1998) Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes 47:550-558
223. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ (2000) Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102:829-832
224. Narne P, Ponnaluri KC, Singh S et al (2012) Relationship between angiotensin-converting enzyme gene insertion/deletion polymorphism, angiographically defined coronary artery disease and myocardial infarction in patients with type 2 diabetes mellitus. J Renin Angiotensin Aldosterone Syst 13:478-486
225. Ng MC, Miyake K, So WY et al (2005) The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia 48:2018-2024
226. Nishio K, Kashiki S, Tachibana H, Kobayashi Y (2011) Angiotensin- converting enzyme and bradykinin gene polymorphisms and cough: a meta-analysis. World J Cardiol 3:329-336
227. Niu W, Qi Y, Gao P, Zhu D (2010) A meta-analysis of the bradykinin B2 receptor gene -58C/T polymorphism with hypertension. Clin Chim Acta 411:324-328
228. Nolly H, Carbini LA, Scicli G et al (1994) A local kallikrein-kinin system is present in rat hearts. Hypertension 23:919-923
229. Nossent AY, Hansen JL, Doggen C et al (2011) SNPs in microRNA binding sites in 3'-UTRs of RAAS genes influence arterial blood pressure and risk of myocardial infarction. Am J Hypertens 24:999-1006
230. Nussberger J, Cugno M, Amstutz C et al (1998) Plasma bradykinin in angio-oedema. Lancet 351:1693-1697
231. Nuutila P, Raitakari M, Laine H et al (1996) Role of blood flow in regulating insulin-stimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxyglucose and positron emission tomography. J Clin Invest 97:1741-1747
232. Oh-Ishi S, Hayashi I, Hayashi M et al (1986) Evidence for a role of the plasma kallikrein-kinin system in acute inflammation: reduced exudation during carrageenin- and kaolin-pleurisies in kininogen-deficient rats. Agents Actions 18:450-454
233. Olson TP, Frantz RP, Turner ST et al (2009) Gene variant of the bradykinin B2 receptor influences pulmonary arterial pressures in heart failure patients. Clin Med Circ Respirat Pulm Med 3:9-17
234. Orfila C, Bompart G, Lepert JC et al (1993) Renal immunolocalization of kallikrein in cisplatin nephrotoxicity in rats. Histochem J 25:772-777
235. Otowa T, Kawamura Y, Nishida N et al (2012) Meta-analysis of genome-wide association studies for panic disorder in the Japanese population. Transl Psychiatry Nov 13(2):e186. doi:10.1038/ tp.2012.89
236. Pan HL, Chen SR, Scicli GM, Carretero OA (2000) Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning. Am J Physiol Heart Circ Physiol 279:H116-H121
237. Parenti A, Morbidelli L, Ledda F et al (2001) The bradykinin/B1 receptor promotes angiogenesis by up-regulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15:1487-1489
238. Pawluczyk IZ, Tan EK, Lodwick D, Harris K (2008) Kallikrein gene 'knock-down' by small interfering RNA transfection induces a profibrotic phenotype in rat mesangial cells. J Hypertens 26:93-101
239. Pesquero JB, Araujo RC, Heppenstall PA et al (2000) Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 97:8140-8145
240. Petho G, Reeh PW (2012) Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. Physiol Rev 92:1699-1775
241. Picard N, Van Abel M, Campone C et al (2005) Tissue kallikrein-deficient mice display a defect in renal tubular calcium absorption. J Am Soc Nephrol 16:3602-3610
242. Picard N, Eladari D, El Moghrabi S et al (2008) Defective ENaC processing and function in tissue kallikrein-deficient mice. J Biol Chem 283:4602-4611
243. Pons S, Griol-Charhbili V, Heymes C et al (2008) Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Eur J Heart Fail 10:343-351
244. Popadic Gacesa JZ, Momcilovic M, Veselinovic I et al (2012) Bradykinin type 2 receptor -9/-9 genotype is associated with triceps brachii muscle hypertrophy following strength training in young healthy men. BMC Musculoskelet Disord 13:217. doi:10.1186/1471-2474-13-217
245. Potier L, Waeckel L, Richer C et al (2011) Tissue kallikrein, blood pressure regulation, and hypertension: insight from genetic kallikrein deficiency. Biol Chem 394:329-333
246. Potier L, Waeckel L, Vincent MP et al (2013) Selective kinin receptor agonists as cardioprotective agents in myocardial ischemia and diabetes. J Pharmacol Exp Ther 346:23-30
247. Potier L, Waeckel L, Fumeron F et al (2014) Tissue kallikrein deficiency, insulin resistance and diabetes in mouse and man. J Endocrinol. 2014 Mar 5. [Epub ahead of print]
248. Pouliot M, Talbot S, Sénécal J et al (2012) Ocular application of the kinin B1 receptor antagonist LF22-0542 inhibits retinal inflammation and oxidative stress in streptozotocin-diabetic rats. PLoS ONE 7:e33864
249. Pretorius MM, Gainer JV, Van Guilder GP et al (2008) The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clin Pharmacol Ther 83:122-129
250. Rett K, Wicklmayr M, Dietze GJ, Häring HU (1996) Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 45:S66-S69
251. Rigat B, Hubert C, Alhenc-Gelas F et al (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346
252. Rodrigues ES, Silva RF, Martin RP et al (2013) Evidence that kinin B2 receptor expression is upregulated by endothelial overexpression of B1 receptor. Peptides 42:1-7
253. Samani NJ, Thompson JR, O'Toole L et al (1996) A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94:708-712
254. Sanchez de Miguel L, Neysari S, Jakob S et al (2008) B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart. Cardiovasc Res 80:106-113
255. Sarzynski MA, Rankinen T, Sternfeld B et al (2011) SNP-by-fitness and SNP-by-BMI interactions from seven candidate genes and incident hypertension after 20 years of followup: the CARDIA Fitness Study. J Hum Hypertens 25:509-518
256. Saunders CJ, Xenophontos SL, Cariolou MA et al (2006) The bradykinin beta 2 receptor (BDKRB2) and endothelial nitric oxide synthase 3 (NOS3) genes and endurance performance during Ironman Triathlons. Hum Mol Genet 15:979-987
257. Savard M, Labonté J, Dubuc C et al (2013) Further pharmacological evaluation of a novel synthetic peptide bradykinin B2 receptor agonist. Biol Chem 394:353-360
258. Sayed-Tabatabaei FA, Oostra BA, Isaacs A et al (2006) ACE polymorphisms. Circ Res 98:1123-1133
259. Schanstra JP, Neau E, Drogoz P et al (2002) In vivo bradykinin B2 receptor activation reduces renal fibrosis. J Clin Invest 110:371-379
260. Schanstra JP, Duchene J, Praddaude F et al (2003) Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284:H1904-H1908
261. Schulze-Topphoff U, Prat A et al (2009) Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15:788-793
262. Seguin T, Buleon M, Destrube M et al (2008)Hemodynamic and renal involvement ofB1 andB2 kinin receptors during the acute phase of endotoxin shock in mice. Int Immunopharmacol 8:217-221
263. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320:1161-1165
264. Sgourou A, Fotopoulos V, Kontos V et al (2012) Association of genome variations in the reninangiotensin system with physical performance. Hum Genomics 6:24. doi:10.1186/ 1479-7364-6-24
265. Shariat-Madar Z, Mahdi F, Warnock M et al (2006) Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108:192-199
266. Shesely EG, Hu CB, Alhenc-Gelas F et al (2006) A second expressed kininogen gene in mice. Physiol Genomics 26:152-157
267. Shiuchi T, Cui TX, Wu L, Nakagami H et al (2002) ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 40:329-334
268. Shneder OV, Obrezan AG, Makeeva ED et al (2004) Impact of angiotensin-converting enzyme, angiotensinogen, endothelial NO synthase, and bradykinin receptor B2 gene polymorphisms on myocardium in patients with hypertension and in athletes]. Tsitologiia 46:69-78
269. Silva PS, Fontana V, Luizon MR et al (2013) eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol 69:167-177
270. Silvestre JS, Bergaya S, Tamarat R et al (2001) Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 89:678-683
271. Siragy HM, Jaffa AA, Margolius HS, Carey RM (1996) Renin-angiotensin system modulates renal bradykinin production. Am J Physiol 271:R1090-R1095
272. Slim R, Torremocha F, Moreau T et al (2002) Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 13:968-976
273. Sotoodehnia N, Li G, Johnson CO, Lemaitre RN et al (2009) Genetic variation in angiotensinconverting enzyme-related pathways associated with sudden cardiac arrest risk. Heart Rhythm 6:1306-1314. doi:10.1016/j.hrthm.2009. 06.013
274. Spillmann F, Graiani G, Van Linthout S et al (2006) Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen Med 1:235-254
275. Spinetti G, Fortunato O, Cordella D et al (2011) Tissue kallikrein is essential for invasive capacity of circulating proangiogenic cells. Circ Res 108:284-293
276. Steckelings UM, Paulis L, Namsolleck P, Unger T (2012) AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 21:142-146
277. Stewart AG, Piper PJ (1988) Vasodilator actions of acetylcholine, A23187 and bradykinin in the guinea-pig isolated perfused heart are independent of prostacyclin. Br J Pharmacol 95:379-384
278. Stone OA, Richer C, Emanueli C et al (2009) Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol 29:657-664
279. Sun D, Shen M, Li J et al (2011) Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3b dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 13:10-14
280. Suhre K, Shin SY, Petersen AK et al (2011) Human metabolic individuality in biomedical and pharmaceutical research. Nature 477:54-60
281. Talbot S, Couture R (2012) Emerging role of microglial kinin B1 receptor in diabetic pain neuropathy. Exp Neurol. 234:373-381
282. Tang SC, Chan LY, Leung JC et al (2011) Additive renoprotective effects of B2-kinin receptor blocker and PPAR-c agonist in uninephrectomized db/db mice. Lab Invest 91:1351-1362
283. Tan Y, Keum JS, Wang B et al (2007) Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy. Am J Physiol Renal Physiol 293:F1026-F1035
284. Tazón-Vega B, Vilardell M, Pérez-Oller L et al (2007) Study of candidate genes affecting the progression of renal disease in autosomal dominant polycystic kidney disease type 1. Nephrol Dial Transplant 22:1567-1577
285. Thuringer D, Maulon L, Frelin C (2002) Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitricoxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277:2028-2032
286. Tomita H, Sanford RB, Smithies O, Kakoki M (2012) The kallikrein-kinin system in diabetic nephropathy. Kidney Int 81:733-744
287. Trabold F, Pons S, Hagege AA et al (2002) Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 40:90-95
288. Tschöpe C, Walther T, Yu M et al (1999) Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology 44:35-42
289. Tschöpe C, Heringer-Walther S, Koch M et al (2000) Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. J Hypertens 18:223-228
290. Tschöpe C, Spillmann F, Altmann C et al (2004a) The bradykinin B1 receptor contributes to the cardioprotective effects of AT1 blockade after experimental myocardial infarction. Cardiovasc Res 61:559-569
291. Tschöpe C, Walther T, Königer J et al (2004b) Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18:828-835
292. Tschöpe C, Westermann D (2008) Development of diabetic cardiomyopathy and the kallikreinkinin system - new insights from B1 and B2 receptor signaling. Biol Chem 389:707-711
293. Tsianos GI, Evangelou E, Boot A et al (2010) Associations of polymorphisms of eight muscle- or metabolism-related genes with performance in mount olympus marathon runners. J Appl Physiol 108:567-574
294. Ungi I, Pálinkás A, Nemes A et al (2008) Myocardial protection with enalaprilat in patients unresponsive to ischemic preconditioning during percutaneous coronary intervention. Can J Physiol Pharmacol 86:827-834
295. Van Guilder GP, Pretorius M, Luther JM et al (2008) Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 51:454-459
296. Vegh A, Szekeres L, Parratt JR (1991) Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmias in anaesthetized dogs. Br J Pharmacol 104:294-295
297. Vinci JM, Gill JR Jr, Bowden RE et al (1978) The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest 61:1671-1682
298. Vora JP, Oyama TT, Thompson MM, Anderson S (1997) Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes 46:107-112
299. Waeckel L, Potier L, Chollet C et al (2012) Antihypertensive role of tissue kallikrein in hyperaldosteronism in the mouse. Endocrinology 153:3886-3896
300. Waeckel L, Potier L, Richer C et al (2013) Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thromb Haemost 110:476-483
301. Wang J, Xiong W, Yang Z et al (1994) Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 23:236-243
302. Wang C, Chao L, Chao J (1995) Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats. J Clin Invest 95:1710-1716
303. Wang DZ, Chao L, Chao J (1997) Hypotension in transgenic mice overexpressing human bradykinin B2 receptor. Hypertension 29(1Pt 2):488-493
304. Wang D, Yoshida H, Song Q et al (2000) Enhanced renal function in bradykinin B(2) receptor transgenic mice. Am J Physiol Renal Physiol 278:F484-F491
305. Wang B, Dang A, Liu G (2001) Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. Hypertens Res 24:299-302
306. Weiss AS, Gallin JI, Kaplan AP (1974) Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest 53:622-633
307. Wende AR, Soto J, Olsen CD et al (2010) Loss of bradykinin signaling does not accelerate the development of cardiac dysfunction in type 1 diabetic akita mice. Endocrinology 151:3536-3542
308. Westermann D, Lettau O, Sobirey M et al (2008) Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor. Biol Chem 389:713-718. doi: 10.1515/BC.2008.070
309. Westermann D, Walther T, Savvatis K et al (2009) Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes 58:1373-1381
310. Wiemer G, Schölkens BA, Becker RH, Busse R (1991) Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 18:558-563
311. Williams AG, Dhamrait SS, Wootton PT et al (2004) Bradykinin receptor gene variant and human physical performance. J Appl Physiol 96:938-942
312. Wolf WC, Yoshida H, Agata J et al (2000) Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.Kidney Int 58:730-739
313. Woo SW, Bang S, Chung MW et al (2009) Lack of association between ACE and bradykinin B2 receptor gene polymorphisms and ACE inhibitor-induced coughing in hypertensive Koreans. J Clin Pharm Ther 34:561-567
314. Wu H, Roks AJ, Leijten FP et al (2014) Genetic variation and gender determine bradykinin type 1 receptor responses in human tissue: implications for the ACE-inhibitor-induced effects in patients with coronary artery disease. Clin Sci 126:441-449
315. Xia CF, Yin H, Yao YY et al (2006) Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum Gene Ther 17:206-219
316. Xing-Sheng Y, Yong-Zhi L, Jie-Xin L et al (2010) Genetic influence on baroreflex sensitivity in normotensive young men. Am J Hypertens 23:655-659. (Erratum in: Am J Hypertens 23:702)
317. Xu J, Carretero OA, Sun Y et al (2005) Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 45:747-753
318. Xu J, Carretero OA, Shesely EG et al (2009) The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol 94:322-329
319. Xu J, Carretero OA, Zhu L et al (2013) Protective role of AT2 and B1 receptors in kinin B2 receptor knockout mice with myocardial infarction. Clin Sci (Lond) 124:87-96
320. Yang XP, Liu YH, Scicli GM et al (1997) Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen-deficient rats. Hypertension 30:735-740
321. Yang XP, Liu YH, Mehta D et al (2001) Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. Circ Res 88:1072-1079
322. Yao YY, Yin H, Shen B et al (2007) Tissue kallikrein infusion prevents cardiomyocyte apoptosis inflammation and ventricular remodeling after myocardial infarction. Regul Pept 140:12-20
323. Yayama K, Wang C, Chao L, Chao J (1998) Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 31:1104-1110
324. Yin H, Chao J, Bader M, Chao L (2007) Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 28:1383-1389
325. Yin H, Chao L, Chao J (2008) Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion. Life Sci 82:156-165
326. Yosipiv IV, Dipp S, El-Dahr SS (2001) Targeted disruption of the bradykinin B(2) receptor gene in mice alters the ontogeny of the renin-angiotensin system. Am J Physiol Renal Physiol 281:F795-F801
327. Zaika O, Mamenko M, O'Neil RG, Pochynyuk O (2001) Bradykinin acutely inhibits activity of the epithelial Na + channel in mammalian aldosterone-sensitive distal nephron. Am J Physiol Renal Physiol 300:F1105-F1115
328. Zakrzewski-Jakubiak M, de Denus S, Dubé MP et al (2008) Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure. Br J Clin Pharmacol 65:742-751
329. Zee RY, Rao VS, Paster RZ et al (1998) Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension 31:925-928
330. Zhou JB, Liu C, Niu WY et al (2012) Contributions of renin-angiotensin system-related gene interactions to obesity in a Chinese population. PLoS ONE 7:e42881
331. Zhu X, Chang YP, Yan D et al (2003) Associations between hypertension and genes in the reninangiotensin system. Hypertension 41:1027-1034
332. Zinner SH, Margolius HS, Rosner B et al (1976) Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 104:124-132
333. Zychma MJ, Gumprecht J, Zukowska-Szczechowska E, Grzeszczak W (1999) Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. The end-stage renal disease study group. J Am Soc Nephrol 10:2120-2124
334. Zychma MJ, Gumprecht J, Trautsolt W et al (2003) Polymorphic genes for kinin receptors, nephropathy and blood pressure in type 2 diabetic patients. Am J Nephrol 23:112-116